Cemiplimab Improves Health-Related Quality of Life (HRQoL) and Reduces Pain in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Results from a Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial

Guilherme Rabinowits

Cemiplimab Improves Health-Related Quality of Life (HRQoL) and Reduces Pain in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Results from a Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial

Guilherme Rabinowits

Herbert Wertheim Cancer Institute

Research output: Contribution to conference › Presentation

Original language	American English
State	Published - Oct 1 2020

Access to Document

Cemiplimab Improves Health-Related Quality of Life (HRQoL) and ReFinal published version, 227 KBLicense: Unspecified

Cite this

@conference{ffddd9a72c2f42f6937d692206ab49e0,

title = "Cemiplimab Improves Health-Related Quality of Life (HRQoL) and Reduces Pain in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Results from a Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial",

author = "Guilherme Rabinowits",

year = "2020",

month = oct,

day = "1",

language = "American English",

}

TY - CONF

T1 - Cemiplimab Improves Health-Related Quality of Life (HRQoL) and Reduces Pain in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Results from a Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial

AU - Rabinowits, Guilherme

PY - 2020/10/1

Y1 - 2020/10/1

UR - https://scholarlycommons.baptisthealth.net/se-all-publications/3879

M3 - Presentation

ER -

Cemiplimab Improves Health-Related Quality of Life (HRQoL) and Reduces Pain in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Results from a Post Hoc Exploratory Analysis of a Phase 2 Clinical Trial

Access to Document

Other files and links

Cite this